| First Author | Kun EHS | Year | 2020 |
| Journal | Sci Rep | Volume | 10 |
| Issue | 1 | Pages | 20678 |
| PubMed ID | 33244099 | Mgi Jnum | J:299702 |
| Mgi Id | MGI:6491047 | Doi | 10.1038/s41598-020-77666-y |
| Citation | Kun EHS, et al. (2020) Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations. Sci Rep 10(1):20678 |
| abstractText | How different KRAS variants impact tumor initiation and progression in vivo has not been thoroughly examined. We hypothesize that the ability of either KRAS(G12D) or KRAS(G12V) mutations to initiate tumor formation is context dependent. Amhr2-Cre mice express Cre recombinase in tissues that develop into the fallopian tubes, uterus, and ovaries. We used these mice to conditionally express either the KRAS(G12V/+) or KRAS(G12D/+) mutation. Mice with the genotype Amhr2-Cre Pten((fl/fl)) Kras(G12D/+)(G12D mice) had abnormal follicle structures and developed low-grade serous ovarian carcinomas with 100% penetrance within 18 weeks. In contrast, mice with the genotype Amhr2-Cre Pten((fl/fl)) Kras(G12V/+) (G12V mice) had normal follicle structures, and about 90% of them developed uterine tumors with diverse histological features resembling those of leiomyoma and leiomyosarcoma. Granulosa cell tumors also developed in G12V mice. Differences in cell-signaling pathways in the uterine tissues of G12D and G12V mice were identified using RNA sequencing and reverse-phase protein array analyses. We found that CTNNB1, IL1A, IL1B, TNF, TGFB1, APP, and IL6 had the higher activity in G12V mice than in G12D mice. These mouse models will be useful for studying the differences in signaling pathways driven by Kras(G12V/+) or Kras(G12D/+) mutations to aid development of targeted therapies for specific KRAS mutant variants. Our leiomyoma model driven by the Kras(G12V/+) mutation will also be useful in deciphering the malignant progression from leiomyoma to leiomyosarcoma. |
